The transactions highlighted below are representative of Greenhill engagements. In addition, the Firm has completed many engagements that were not publicly-disclosed.
Recent Transactions
Sort By
12-Jul-21
Pending
$1.7 billion
Target:
Tate & Lyle PLC’s Primary Products business in North America and Latin America (50% stake)
Acquiror:
KPS Capital Partners
Advising Tate & Lyle PLC, a leading UK-based global provider of food and beverage ingredients and solutions, on its sale of a controlling stake in its Primary Products business in North America and Latin America
04-Oct-16
$223 million
Target:
US rights to Toprol-XL (AstraZeneca)
Acquiror:
Aralez Pharmaceuticals Inc.
Advised Aralez Pharmaceuticals Inc., a global specialty pharmaceutical company in connection with the financing of its acquisition of the US rights to cardiovascular drug Toprol-XL (metoprolol succinate) and its Authorized Generic from AstraZeneca.
08-Aug-11
$11.0 billion
Target:
Coal and Allied Industries Limited
Acquiror:
Rio Tinto Limited / Mitsubishi Corporation
Advised Coal and Allied Industries Limited, an Australian based coal mining company, in relation to an acquisition proposal from Rio Tinto Limited and Mitsubishi Corporation to acquire all the outstanding shares in the company not already held by Rio Tinto and Mitsubishi
06-Aug-08
$10.7 billion
Target:
Lonmin plc
Acquiror:
Xstrata plc
Advised Lonmin plc, a major producer of Platinum Group Metals, regarding an unsolicited pre-conditional offer for the company by Xstrata plc, a global diversified mining company
23-Oct-03
$3.1 billion
Target:
Debenhams plc
Acquiror:
Baroness Retail (a consortium of CVC, TPG and Merrill Lynch)
Advised the independent committee of the Board of Directors of Debenhams plc, a leading UK department store chain, with regards to the sale of the company